Genetic and Genomic Factors in Prostate Cancer among African American Men
Official title: Genetic and Genomic Variation in Prostate Cancer
Funded at Dana-Farber Cancer Inst · NIH-11535328 · Data updated 2026-11-12
A study to understand how inherited genes and tumor genetics influence the risk and behavior of prostate cancer in men, especially those of African descent.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | January 7, 2022 |
| Project end | April 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $44,377 |
| NIH project number | 3R01CA259200-05S5 |
| Project ID | NIH-11535328 on NIH RePORTER |
Who could benefit from this research
✓Could help
Men with or at risk for prostate cancer, particularly individuals of African ancestry or American men affected by prostate cancer.
✕Less likely to help
The study may not directly benefit individuals who do not have or are not at risk for prostate cancer or who do not share the genetic backgrounds analyzed.
What this research studies
This project looks at how germline and tumor DNA variations relate to how often prostate cancer occurs and how aggressive it is. It will analyze thousands of genetic variants and tumor mutation patterns to see how they affect cancer risk and progression. The researchers aim to improve how genetic information is translated into clinical care for American men with prostate cancer. By focusing on diverse genotypes, the study seeks to reduce misdiagnoses and improve personalized treatment. The work will inform future strategies for prevention, diagnosis, and therapy based on an individual’s genetic makeup.
Why it matters
Potential benefit: If successful, this research could lead to better risk prediction and more tailored treatments for prostate cancer, especially for men of African descent.
How similar studies have gone: Prior studies have linked germline and somatic variations to prostate cancer risk and progression, but substantial variation across populations remains to be clarified.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Rebbeck, Timothy Richard — Dana-Farber Cancer Inst
- Study coordinator: Rebbeck, Timothy Richard
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.